Exelixis Net Income
| EXEL Stock | USD 41.69 0.95 2.33% |
As of the 4th of March, Exelixis shows the Variance of 4.64, standard deviation of 2.15, and Mean Deviation of 1.52. Exelixis technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Exelixis mean deviation, information ratio, as well as the relationship between the Information Ratio and potential upside to decide if Exelixis is priced favorably, providing market reflects its regular price of 41.69 per share. Given that Exelixis has information ratio of (0.05), we urge you to verify Exelixis's prevailing market performance to make sure the company can sustain itself at a future point.
Exelixis Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 4.2109 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 782.6 M | 821.7 M | |
| Net Income From Continuing Ops | 782.6 M | 821.7 M | |
| Net Income Applicable To Common Shares | 209.6 M | 220.1 M | |
| Net Income Per Share | 2.88 | 0.65 | |
| Net Income Per E B T | 0.83 | 0.81 |
Exelixis | Net Income | Build AI portfolio with Exelixis Stock |
Historical Net Income data for Exelixis serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Exelixis represents a compelling investment opportunity.
Latest Exelixis' Net Income Growth Pattern
Below is the plot of the Net Income of Exelixis over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Exelixis financial statement analysis. It represents the amount of money remaining after all of Exelixis operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Exelixis' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Exelixis' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 782.57 M | 10 Years Trend |
|
Net Income |
| Timeline |
Exelixis Net Income Regression Statistics
| Arithmetic Mean | 187,227,088 | |
| Geometric Mean | 201,878,830 | |
| Coefficient Of Variation | 184.16 | |
| Mean Deviation | 266,453,633 | |
| Median | 154,227,000 | |
| Standard Deviation | 344,805,539 | |
| Sample Variance | 118890.9T | |
| Range | 1.1B | |
| R-Value | 0.77 | |
| Mean Square Error | 51569.4T | |
| R-Squared | 0.59 | |
| Significance | 0.0003 | |
| Slope | 52,597,086 | |
| Total Sum of Squares | 1902253.8T |
Exelixis Net Income History
Other Fundumenentals of Exelixis
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Exelixis Net Income component correlations
Exelixis Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Exelixis is extremely important. It helps to project a fair market value of Exelixis Stock properly, considering its historical fundamentals such as Net Income. Since Exelixis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Exelixis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Exelixis' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. Projected growth potential of Exelixis fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Exelixis assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.842 | Earnings Share 2.76 | Revenue Per Share | Quarterly Revenue Growth 0.056 | Return On Assets |
Investors evaluate Exelixis using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Exelixis' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Exelixis' market price to deviate significantly from intrinsic value.
It's important to distinguish between Exelixis' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Exelixis should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Exelixis' market price signifies the transaction level at which participants voluntarily complete trades.
Exelixis 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Exelixis' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Exelixis.
| 12/04/2025 |
| 03/04/2026 |
If you would invest 0.00 in Exelixis on December 4, 2025 and sell it all today you would earn a total of 0.00 from holding Exelixis or generate 0.0% return on investment in Exelixis over 90 days. Exelixis is related to or competes with Aprea Therapeutics, Adial Pharmaceuticals, Kiora Pharmaceuticals, Cardio Diagnostics, and Phio Pharmaceuticals. Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization ... More
Exelixis Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Exelixis' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Exelixis upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 12.62 | |||
| Value At Risk | (3.26) | |||
| Potential Upside | 3.61 |
Exelixis Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Exelixis' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Exelixis' standard deviation. In reality, there are many statistical measures that can use Exelixis historical prices to predict the future Exelixis' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.18) | |||
| Treynor Ratio | (0.12) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Exelixis' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Exelixis March 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.11) | |||
| Mean Deviation | 1.52 | |||
| Coefficient Of Variation | (3,396) | |||
| Standard Deviation | 2.15 | |||
| Variance | 4.64 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.18) | |||
| Treynor Ratio | (0.12) | |||
| Maximum Drawdown | 12.62 | |||
| Value At Risk | (3.26) | |||
| Potential Upside | 3.61 | |||
| Skewness | (0.11) | |||
| Kurtosis | 1.48 |
Exelixis Backtested Returns
Exelixis secures Sharpe Ratio (or Efficiency) of -0.0456, which denotes the company had a -0.0456 % return per unit of risk over the last 3 months. Exelixis exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Exelixis' Mean Deviation of 1.52, standard deviation of 2.15, and Variance of 4.64 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.61, which means possible diversification benefits within a given portfolio. As returns on the market increase, Exelixis' returns are expected to increase less than the market. However, during the bear market, the loss of holding Exelixis is expected to be smaller as well. At this point, Exelixis has a negative expected return of -0.1%. Please make sure to confirm Exelixis' potential upside, and the relationship between the total risk alpha and daily balance of power , to decide if Exelixis performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.04 |
Virtually no predictability
Exelixis has virtually no predictability. Overlapping area represents the amount of predictability between Exelixis time series from 4th of December 2025 to 18th of January 2026 and 18th of January 2026 to 4th of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Exelixis price movement. The serial correlation of 0.04 indicates that only as little as 4.0% of current Exelixis price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.04 | |
| Spearman Rank Test | -0.21 | |
| Residual Average | 0.0 | |
| Price Variance | 1.25 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Exelixis Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Exelixis reported net income of 782.57 M. This is 129.3% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 37.06% lower than that of the firm.
Exelixis Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Exelixis' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Exelixis could also be used in its relative valuation, which is a method of valuing Exelixis by comparing valuation metrics of similar companies.Exelixis is currently under evaluation in net income category among its peers.
Exelixis ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Exelixis' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Exelixis' managers, analysts, and investors.Environmental | Governance | Social |
Exelixis Institutional Holders
Institutional Holdings refers to the ownership stake in Exelixis that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Exelixis' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Exelixis' value.| Shares | Dimensional Fund Advisors, Inc. | 2025-12-31 | 4.3 M | Morgan Stanley - Brokerage Accounts | 2025-09-30 | 3.2 M | Genworth Financial Wealth Mgmt Inc | 2025-09-30 | 3.2 M | Caisse De Depot Et Placement Du Quebec | 2025-12-31 | 2.7 M | Ubs Group Ag | 2025-09-30 | 2.7 M | Stephens Inv Mgmt Group Llc | 2025-12-31 | 2.5 M | Allianz Asset Management Ag | 2025-09-30 | 2.5 M | Norges Bank | 2025-12-31 | 2.4 M | Bank Of America Corp | 2025-09-30 | 2.4 M | Blackrock Inc | 2025-09-30 | 29.4 M | Vanguard Group Inc | 2025-12-31 | 25.5 M |
Exelixis Fundamentals
| Return On Equity | 0.36 | ||||
| Return On Asset | 0.19 | ||||
| Profit Margin | 0.34 % | ||||
| Operating Margin | 0.39 % | ||||
| Current Valuation | 9.77 B | ||||
| Shares Outstanding | 259.71 M | ||||
| Shares Owned By Insiders | 2.41 % | ||||
| Shares Owned By Institutions | 97.59 % | ||||
| Number Of Shares Shorted | 28.81 M | ||||
| Price To Earning | 48.17 X | ||||
| Price To Book | 4.93 X | ||||
| Price To Sales | 4.71 X | ||||
| Revenue | 2.32 B | ||||
| Gross Profit | 2.24 B | ||||
| EBITDA | 921.76 M | ||||
| Net Income | 782.57 M | ||||
| Cash And Equivalents | 1.53 B | ||||
| Cash Per Share | 4.77 X | ||||
| Total Debt | 173.04 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 6.08 X | ||||
| Book Value Per Share | 8.23 X | ||||
| Cash Flow From Operations | 884.27 M | ||||
| Short Ratio | 11.24 X | ||||
| Earnings Per Share | 2.76 X | ||||
| Price To Earnings To Growth | 2.27 X | ||||
| Target Price | 46.83 | ||||
| Number Of Employees | 1.08 K | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 10.92 B | ||||
| Total Asset | 2.84 B | ||||
| Retained Earnings | (76.83 M) | ||||
| Working Capital | 1.04 B | ||||
| Current Asset | 178.66 M | ||||
| Current Liabilities | 52.25 M | ||||
| Net Asset | 2.84 B |
About Exelixis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Exelixis's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exelixis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exelixis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. Projected growth potential of Exelixis fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Exelixis assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.842 | Earnings Share 2.76 | Revenue Per Share | Quarterly Revenue Growth 0.056 | Return On Assets |
Investors evaluate Exelixis using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Exelixis' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Exelixis' market price to deviate significantly from intrinsic value.
It's important to distinguish between Exelixis' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Exelixis should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Exelixis' market price signifies the transaction level at which participants voluntarily complete trades.